Active, Not Recruiting
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more
- Locations
-
- City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
- Yale New Haven Hospital New Haven, Connecticut, United States
- Moffitt Cancer Center Tampa, Florida, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States